HCV Updates and Insights
Direct-acting antivirals improve access to care and cure for patients with HIV and chronic HCV infection.
Collins LF, et al. Open Forum Infect Dis. 2018;5(1):ofx264.
Ladino M, et al. World J Hepatol. 2017;9(19):833-839.
Universal opt-out screening for hepatitis C virus (HCV) within correctional facilities is an effective intervention to improve public health.
Morris MD, et al. Int J Prison Health. 2017;13(3-4):192-199.
Norton BL, et al. J Subst Abuse Treat. 2017;75:38-42.
Perlman DC, Jordan AE. Curr HIV/AIDS Rep. 2018;15(2):96-112.
Visconti AJ, et al. Am Fam Physician. 2019;99(2):109-116.
Risk factors for hepatitis C virus reinfection after sustained virologic response in patients coinfected with HIV.
Young J, et al. Clin Infect Dis. 2017;64(9):1154-1162.
Action and Advocacy
EDUCATION AND TRAINING
Gulati R, et al. Clin Liver Dis. 2018;11(2):48-51.
The Hepatitis Education Project provides support, education, advocacy, and direct services for people affected by hepatitis, and works to raise hepatitis awareness among patients, medical providers, and the general public.
The National Hepatitis Corrections Network (NHCN) supports a public health approach to hepatitis education, prevention, testing, and treatment in prisons and jails.
Project ECHO is a collaborative, telecommunications-based model of medical education and care management designed to train primary care clinicians to provide specialty care in rural and underserved areas.
PUBLIC POLICY: EXPANSION OF ACCESS TO CARE
Akiyama MJ, et al. Am J Public Health. 2018;108(5):607-608.
Center for Health Law and Policy Innovation of Harvard Law School (CHLPI) and National Viral Hepatitis Roundtable (NVHR).
Together, CHLPI and NVHR continue to play a pivotal role in removing Medicaid restrictions on HCV treatment. An interactive map allows you to see each state’s Medicaid restrictions. Last updated November 2018.
Expansion of treatment for hepatitis C virus infection by task shifting to community-based nonspecialist providers: a nonrandomized clinical trial.
Kattakuzhy S, et al. Ann Intern Med. 2017;167(5):311-318.
NASEN provides a directory of syringe exchange programs that can be located by zip code, landmark, city, or state.
SAMHSA provides confidential and anonymous information on substance abuse and mental health treatment facilities throughout the United States and its territories.
SAMHSA provides numerous links to nonprofit associations, federal agencies, and patient groups that offer support for providers of medication-assisted treatment (MAT), as well as their patients and families.
American Liver Foundation, 2018.
The American Liver Foundation’s Hepatitis C Information Center website is a dedicated online information and resource center created in support of individuals impacted by HCV infection.
Project Inform provides up-to-date information to help people living with HIV and HCV make the best choices regarding their treatment and care.
Complete List of References Associated With Figure Titled Real-World Evidence.
Conway B, et al. American Association for the Study of Liver Diseases. The Liver Meeting® 2016 – AASLD. November 11−15, 2016; Boston, MA. Poster 1992.
Dore GJ, et al. Ann Intern Med. 2016;165(9):625-634.
Drugs@FDA. 2018. https://www.accessdata.fda.gov/scripts/cder/daf/.
Grebely J, et al. Clin Infect Dis. 2016;63(11):1405-1411.
Grebely J, et al. Clin Infect Dis. 2016;63(11):1479-1481.
Grebely J, et al. J Hepatol. 2017;66:S513-S514.
Kiser JJ. Top Antivir Med. 2016;24(3):106-110.
Naggie SD, et al. N Engl J Med. 2015;373(8):705-713.
Osinusi A, et al. JAMA. 2015;313(12):1232-1239.
Puoti M, et al. J Hepatol. 2018;69(2):293-300.
Rockstroh JK, et al. Clin Infect Dis. 2018;67(7):1010-1017.
Rockstroh JK, et al. Lancet HIV. 2015;2(8):e319-e327.
Rockstroh JK. European Association for the Study of the Liver. The International Liver Congress™ − EASL 2017. April 19-23, 2017; Amsterdam, The Netherlands.
Sulkowski MS, et al. JAMA. 2015;313(12):1223-1231.
Wyles D, et al. Clin Infect Dis. 2017;65(1):6-12.
Zeuzem S, et al. Ann Intern Med. 2015;163(1):1-13.
Realities, Challenges, and Opportunities to Improve Care
The PCPs Role in Preventing HIV
What Do You Know About PrEP?
Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care
Advances in the Diagnosis and Treatment of Nonalcoholic Steatohepatitis
What Do You Know About PrEP?
Got it? Treat it!
The Critical Role of the Community Pharmacist
Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.
Volume 1: Rapid ART Initiation: A New Addition to the HIV-Care Tool Box
The Emerging Role of the Diabetologist
Key Issues Impacting OB/GYN Practice
An Interactive Experience Highlighting Recent Clinical Advances
Hot Topics in HBV, HCV, and NASH
Emerging Concepts in Patient Management
Building Your Understanding to Combat a Growing Problem
Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice
Why It Matters in OB/GYN Practice Today
A Treater’s Guide to Optimizing Care in the Aging Patient with Comorbidities
How the Pharmacist Can Make a Difference
HIV Can Be Prevented— Are You Doing Your Part?
Rapid Start ART — A New Model for HIV Care
Understanding the Growing Syndemic — Opioids, HCV, and HIV
Appraising the Therapeutic Armamentarium in Moderate and Severe Disease
A PrEP Primer
The PCP’s Role in HCV Elimination
What the Pharmacist Needs to Know about PrEP
The Rapid ART Standard of Care: From Evidence to Healthcare Equity
Maximizing Your Role to Impact Patient Outcomes
Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV
Benefits, Barriers, & Best Practices in an Advancing Field
Practical Solutions Across the Spectrum of Care
A PEP/PrEP Training Guide for Pharmacists
An Interactive Learning Experience
A Focus on Clinical Evidence and Guideline Recommendations
A Critical Step Toward HCV Elimination
Considering the Patient, the Provider, and the Science
A Multidisciplinary Online Mini-Curriculum
Volume 1: A Guided Tour of the Evidence Driving Selection of First-line Advanced Therapies in Moderate to Severe IBD
Debates and Discussions about Monoclonal Antibody Therapies
An Update on Monoclonal Antibody Therapies